Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Cancers|September 23, 2022
Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision MedicineEdoardo Francini, Giuseppe Nicolò Fanelli, Filippo Pederzoli, et al.
Oncotarget|November 16, 2017
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trialsRaphael B Moreira, Marcio Debiasi, Edoardo Francini, et al.
The Prostate|May 1, 2018
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)Edoardo Francini, Kathryn P Gray, Wanling Xie, et al.
Frontiers in Oncology|May 13, 2026
Case Report: Niraparib-abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five casesIsmaela Anna Vascotto, Martina Catalano, Jacopo Venturini, et al.
NPJ Precision Oncology|May 25, 2026
Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applicationsEdoardo Francini, Sara Bleve, Giuseppe Nicolo Fanelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)Pierpaolo Correale, Pierosandro Tagliaferri, Antonella Fioravanti, et al.
Prostate Cancer|November 19, 2011
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxelFilippo Francini, Alessandra Pascucci, Edoardo Francini, et al.
Frontiers in Oncology|February 28, 2022
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is StrengthDaniele Fanale, Lidia Rita Corsini, Chiara Brando, et al.
Clinical Genitourinary Cancer|January 15, 2018
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate CancerEdoardo Francini, Steven Yip, Shubidito Ahmed, et al.
Cancers|August 27, 2021
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate CancerEdoardo Francini, Fang-Shu Ou, Justin Rhoades, et al.
Pageof 8